Accustem Sciences Inc · OTC:ACUT
Accustem Sciences — Investor Presentation (June 2023)
17 slides from Accustem Sciences's investor presentation, Jun 8, 2023
Slide 1: Building Better Oncology Tools
eo = =, ee P< ACCUSTec Building Better Oncology Tools AR ACCUSTEM
Slide 2: Disclaimer
DISCLAIMER This presentation contains forward-looking statements that involve risks and uncertainties. You should not place undue reliance on these forward-looking statements. All statements other than statements of historical facts contained in this presentation are forward-looking statements. The
Slide 3: Company Overview
COMPANY OVERVIEW Our mission at AccuStem is to provide proprietary diagnostic tools that address unanswered clinical questions and have therapeutic-like market and margin opportunities As the only known company evaluating tumor “stemness,” our initial focus will be the commercialization of StemPrint
Slide 4: AccuStem Roadmap to Commercialization
ACCUSTEM ROADMAP TO COMMERCIALIZATION Our focus is commercializing a proprietary genomic test in breast cancer representing an estimated market opportunity greater than $1.3B annually that does not require FDA clearance PHASE 1 PHASE 2 PHASE 3 TARGET CANCER CMS ASSET (ANALYTICAL (CLINICAL (CLINICAL
Slide 5: AccuStem at a Glance
ACCUSTEM AT A GLANCE BREAST CANCER PROGRAM STEMNESS PROGRAM EFFICIENT CORPORATE EXECUTION • In-licensed StemPrintER assay from • Planning to build on current • Proven leadership team with nearly Istituto Europeo di Oncologia (IEO) research of stemness across 60 combined years of experience in differ
Slide 6: The Role of Stemness in Cancer
THE ROLE OF “STEMNESS” IN CANCER The cancer stem cell hypothesis is a fundamental concept in cancer biology • Essentially, all tumors arise from precursor cells that are similar to stem cells; these cancer stem cells are highly adaptable and have the ability to grow indefinitely • This hypothesis an
Slide 7: Validation of StemPrintER in Breast Cancer
VALIDATION OF STEMPRINTER IN BREAST CANCER 1 2 N= 574 N= 644 N= 344 N= 432 StemPrintER is highly prognostic for outcomes StemPrintER outperformed the market leader- in early-stage breast cancer OncotypeDx- in the TransATAC cohort 1. Pece, et al. Ebiomedicine. 2019; 2. Pece, et al. Eur J Cancer. 2022
Slide 8: Clinical Decision Making in Breast Cancer
CLINICAL DECISION MAKING IN BREAST CANCER BIOPSY SURGERY THERAPY Clinical Questions What is the subtype of cancer? Mastectomy vs. lumpectomy? Adjuvant Chemotherapy? Is patient a candidate for NAC? Sentinel node vs. full axillary dissection? Hormone Therapy? How aggressive is the cancer? Radiation Th
Slide 9: Path to Commercialization and Reimbursement in Breast Cancer
PATH TO COMMERCIALIZATION AND REIMBURSEMENT IN BREAST CANCER Q3/Q4 2023 Q4 2023 Early 2024 Late 2024/Early 2025 San Antonio Breast Commercial Launch of Medicare Coverage Anticipated Medicare Cancer Symposium 2023 StemPrintER in Select Application Submission Coverage Approval for StemPrintER Abstract
Slide 10: Breast Cancer Genomics Industry
BREAST CANCER GENOMICS INDUSTRY AccuStem Exact Sciences Agendia Hologic Myriad Genetics Veracyte Breast Cancer Product StemPrintER OncotypeDX MammaPrint Endopredict Prosigna Index Global Serviceable 798,000 562,000 562,000 562,000 562,000 562,000 Market Reimbursement (CMS) N/A $3873 $3873 $3873 $387
Slide 11: AccuStem at a Glance
ACCUSTEM AT A GLANCE BREAST CANCER PROGRAM STEMNESS PROGRAM EFFICIENT CORPORATE EXECUTION • In-licensed StemPrintER assay from • Planning to build on current • Proven leadership team with nearly Istituto Europeo di Oncologia (IEO) research of stemness across 60 combined years of experience in differ
Slide 12: Opportunity in Lung Cancer
OPPORTUNITY IN LUNG CANCER 2M+ new lung cancer diagnoses annually • No genomic tests to inform surgical approach, benefit of radiation StemPrintER may inform treatment planning in patients with early stage lung cancer • By evaluating the underlying "stem" biology of tumors, we believe our test will
Slide 13: Opportunity in Prostate Cancer
OPPORTUNITY IN PROSTATE CANCER 1.4M+ new prostate cancer diagnoses annually • No genomic tests to inform approach to definitive treatment (e.g., surgery, radiation, ablation) StemPrintER may inform treatment planning in patients with localized prostate cancer • By evaluating the underlying "stem" bi
Slide 14: AccuStem at a Glance
ACCUSTEM AT A GLANCE BREAST CANCER PROGRAM STEMNESS PROGRAM EFFICIENT CORPORATE EXECUTION • In-licensed StemPrintER assay from • Planning to build on current • Proven leadership team with nearly Istituto Europeo di Oncologia (IEO) research of stemness across 60 combined years of experience in differ
Slide 15: Our Leadership Team and Approach: A Proven Track Record
OUR LEADERSHIP TEAM AND APPROACH: A PROVEN TRACK RECORD WENDY BLOSSER, CEO Keeren Shah, CFO JOE FLANAGAN, CBO ü 23 years of success building organizations ü 20 years of experience in controllership, ü 15 years of strategic expertise with in Oncology and Women’s Health financial planning and analysis
Slide 16: Investment and Company Highlights
INVESTMENT AND COMPANY HIGHLIGHTS ü Management team with wide-ranging leadership experience across various functional areas, deep relationships with luminary US institutions and a track record of successful launch/relaunch strategies ü Only known company with novel diagnostic platform evaluating tum
Slide 17: Thank You for Your Consideration
THANK YOU FOR YOUR CONSIDERATION [email protected] | Accustem.com
AccuStem Sciences — Investor Presentation (June 2023) on 6ix